Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Is there an interaction between st john's wort and birth control pills?Can you tell me psoriasis dose in cosentyx milligrams?Which specific drugs when combined with lipitor can damage the liver?How does tigecycline's cost affect doctor's prescription rates?Have there been any reported fatalities due to tigecycline overdose?
See the DrugPatentWatch profile for Irbesartan
Irbesartan Lawsuits and Class Actions: What is Known? Irbesartan is an angiotensin II receptor antagonist (ARB) used to treat high blood pressure and diabetic nephropathy. In 2018, several companies involved in the production and manufacturing of irbesartan, including China-based Zhejiang Huahai Pharmaceuticals, Inc., and Teva Pharmaceuticals, announced recalls of the medication due to the presence of potential impurities, specifically N-Nitrosourea (NDEA) and N-Nitrosodimethylamine (NDMA). [1] These impurities are known or possible human carcinogens and have been linked to increased cancer risk. What is a Class Action Lawsuit? A class action lawsuit is a type of civil action in which a large group of people with similar claims are represented by a single lawyer or group of lawyers. In the case of irbesartan, a class action lawsuit could involve numerous individuals who took the medication and now claim to have suffered health problems, including cancer, as a result of the impurities. Irbesartan Lawsuits and Settlements There have been several irbesartan lawsuits filed against pharmaceutical companies and manufacturers, alleging that they failed to properly ensure the quality of the medication. Some manufacturers, such as Teva Pharmaceuticals, have agreed to settlements regarding the contamination of their generic irbesartan products. However, the financial impact and extent of these settlements are not yet public. [2] Timeline of Irbesartan Controversy * 2018: The U.S. Food and Drug Administration (FDA) identifies potential impurities in irbesartan products. * 2018: The FDA announces recalls of irbesartan products due to contamination. * 2019: The FDA reports that numerous manufacturers have failed to properly ensure the quality of their irbesartan products. * Present Day: Ongoing court cases and potential class action lawsuits are being pursued by individuals affected by the contaminated medication. Resources: To stay up-to-date on irbesartan-related news, recalls, and class action lawsuit developments, visit the DrugPatentWatch.com website [3]. Sources: [1] Zhejiang Huahai Pharmaceuticals, Inc. (2018). Voluntary Nationwide Recall of Irbesartan and Irbesartan HCT Tablets due to Presence of NDEA Impurities. [2] Teva Pharmaceuticals (2020). Notice of Class Action Settlements in the Teva Irbesartan Cases. [3] DrugPatentWatch.com.